2013

Researchers propose an alternative therapy to fight testicular cancer refractory to chemotherapy

Researchers at Tumor angiogenesis group at Bellvitge Biomedical Institute of Research (IDIBELL) and the Catalan Institute of Oncology (ICO) led by Francesc Viñals have published a study in the journal Clinical Cancer Research where they propose an alternative treatment to cisplatin resistant testicular cancer patients . 90 % cure rate of testicular tumors Testicular tumor […]

Researchers propose an alternative therapy to fight testicular cancer refractory to chemotherapy Read More »

A free web application developed by the ICO-IDIBELL enables data analysis new generation sequencing

The last two years have seen a significant change in the field of genetic diagnosis , mainly due to the application of technologies next generation sequencing (NGS , next generation sequencing) in medium-capacity devices. The development of these instruments, together with the launch of commercial kits to study a limited number of genes, has allowed

A free web application developed by the ICO-IDIBELL enables data analysis new generation sequencing Read More »

Horizon 2020 launched with €15 billion over first two years

The European Commission has for the first time presented calls for projects under Horizon 2020, the European Union’s €80 billion research and innovation programme. Worth more than €15 billion over the first two years, the funding is intended to help boost Europe’s knowledge-driven economy, and tackle issues that will make a difference in people’s lives.

Horizon 2020 launched with €15 billion over first two years Read More »

Keeping growth in check

Researchers from the Laboratory of Cancer Metabolism (LCM) led by George Thomas at the Bellvitge Biomedical Research Institute (IDIBELL), the Catalan Institute of Oncology (ICO) and the Division of Hematology/ Oncology, University of Cincinnati, have shown that loss of either one of two tumor suppressors, ribosomal proteins RPL5 or RPL11, fail to induce cell-cycle arrest,

Keeping growth in check Read More »

Researchers describe the key role of a protein in the segregation of genetic material during cell division

Researchers at the Cell Cycle Research Group of the Bellvitge Institute of Biomedical Research (IDIBELL) led by Ethel Queralt have reported in the journal PLoS Genetics an article which delve into the regulator mechanisms of mitosis, a key stage of the cell-cycle for the correct transmision of genetic information from parents to sons. Cell-cycle Cells

Researchers describe the key role of a protein in the segregation of genetic material during cell division Read More »

Interactions between genes explain part of the heritability of cancer risk

An international study led by researcher Miguel Angel Pujana of the Bellvitge Institute of Biomedical Research (IDIBELL) and the Catalan Institute of Oncology (ICO) describes a new method that could allow the identification of genetic interactions associated with cancer risk. Genome-wide association studies (ie GWAS) has identified dozens of common genetic variants associated with cancer

Interactions between genes explain part of the heritability of cancer risk Read More »

IDIBELL researcher Antonio Agudo received a special mention at the Pfizer Foundation Awards

Agudo published in the Journal of Clinical Oncology that concluded that 20 percent of all tumors are caused directly by the consumption of snuff The Pfizer Foundation gave the Thursday, November 28, its annual awards Biomedicine. The event, held in Barcelona, ​​ distinguished five medical researches on pneumococcal infections in children, lymphatic leukemia, colorectal cancer,

IDIBELL researcher Antonio Agudo received a special mention at the Pfizer Foundation Awards Read More »

Scroll to Top